全文获取类型
收费全文 | 11223篇 |
免费 | 635篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 106篇 |
儿科学 | 221篇 |
妇产科学 | 309篇 |
基础医学 | 1429篇 |
口腔科学 | 445篇 |
临床医学 | 901篇 |
内科学 | 2784篇 |
皮肤病学 | 134篇 |
神经病学 | 952篇 |
特种医学 | 456篇 |
外科学 | 1881篇 |
综合类 | 34篇 |
预防医学 | 484篇 |
眼科学 | 119篇 |
药学 | 671篇 |
中国医学 | 31篇 |
肿瘤学 | 1005篇 |
出版年
2024年 | 8篇 |
2023年 | 83篇 |
2022年 | 227篇 |
2021年 | 382篇 |
2020年 | 221篇 |
2019年 | 324篇 |
2018年 | 400篇 |
2017年 | 272篇 |
2016年 | 329篇 |
2015年 | 390篇 |
2014年 | 592篇 |
2013年 | 648篇 |
2012年 | 948篇 |
2011年 | 960篇 |
2010年 | 517篇 |
2009年 | 498篇 |
2008年 | 758篇 |
2007年 | 774篇 |
2006年 | 639篇 |
2005年 | 640篇 |
2004年 | 636篇 |
2003年 | 507篇 |
2002年 | 409篇 |
2001年 | 62篇 |
2000年 | 48篇 |
1999年 | 67篇 |
1998年 | 72篇 |
1997年 | 69篇 |
1996年 | 56篇 |
1995年 | 50篇 |
1994年 | 57篇 |
1993年 | 50篇 |
1992年 | 27篇 |
1991年 | 36篇 |
1990年 | 26篇 |
1989年 | 25篇 |
1988年 | 23篇 |
1987年 | 15篇 |
1986年 | 18篇 |
1985年 | 10篇 |
1984年 | 13篇 |
1983年 | 9篇 |
1982年 | 8篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1977年 | 5篇 |
1975年 | 6篇 |
1974年 | 5篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
Fernando Pretel Rute M Gon?alves-de-Andrade Fabio Carlos Magnoli Maria Esther R da Silva Jorge M C Ferreira Carmen W van den Berg Denise V Tambourgi 《Toxicon》2005,45(4):449-458
Loxosceles adelaida spiders (Araneae, Sicariidae) are found near and inside the caves in the Parque Estadual Turistico do Alto Ribeira (PETAR), Sao Paulo, Brazil, which are visited by thousands of tourists every year. Several Loxosceles species are a public health problem in many regions of the world, by causing severe dermonecrosis and/or complement dependent haemolysis upon envenomation. The aim of this study was to characterize the biochemical and biological properties of L. adelaida venom and evaluate the toxic potential of envenomation by this non-synanthropic Loxosceles species. The biological activities of the L. adelaida venom was compared to that of Loxosceles gaucho, a synanthropic species of medical importance in Brazil. L. adelaida venom showed a similar potential to induce haemolysis, dermonecrosis and lethality as L. gaucho venom. L. adelaida crude venom was purified, yielding a 31 kDa component endowed with haemolytic and dermonecrotic activities. In conclusion, we show here that the troglophile Loxosceles species, L. adelaida, commonly found in the complex of caves from PETAR, is potentially able to cause envenomation with the same gravity of those produced by synanthropic species. 相似文献
103.
We conducted a meta-analysis of randomized controlled clinical trials on steroid treatment for multiple sclerosis and optic
neuritis. Of the 25 trials comparing steroids and controls without steroid treatment that we identified 12 were selected for
this review. A meta-analysis was conducted to calculate the overall odds ratio across the studies for the numbers of patients
without functional improvement and with new relapses. The trials included a total of 1714 patients: 998 with multiple sclerosis
and 716 with optic neuritis. Any type of corticosteroids or adrenocorticotropic hormone (ACTH) treatment was considered, as
was any dosage, route of administration, and length of treatment. Main outcome measures were: (a) number of multiple sclerosis
patients who did not improve by at least one point on the EDSS or equivalent scale, or number of optic neuritis patients without
complete recovery of visual acuity at 8 or 30 days and at longer follow-up; (b) number of multiple sclerosis patients with
at least one new relapse, or number of optic neuritis patients in whom definite multiple sclerosis was diagnosed at longer
follow-up. We found that corticosteroids or ACTH produced a significant improvement in disability or visual acuity at 30 days
(odds ratio 0.49; 95 % CI 0.37–0.64). The improvement was not statistically significant at longer follow-up (0.85; 95 % CI
0.67–1.09). The treatment did not significantly reduce the number of patients with relapses (0.74; 95 % CI 0.54–1.01). Both
low and high doses were effective for 30-day improvement, but only high-dose and short-term therapy were factors that identified
subgroups with some reduction in the risk of new relapse. However, the power of the statistical analysis to detect a reliable
difference in the subgroups was low. Steroid treatment is therefore effective in accelerating short-term recovery in patients
with multiple sclerosis or optic neuritis. Whether steroids are also effective in reducing the risk of relapse, and the optimal
dose and length of treatment must still be determined.
Received: 5 August 1999, Received in revised form: 29 December 1999, Accepted: 22 January 2000 相似文献
104.
Fabio Scopesi Silvana Canini Cesare Arioni Massimo Mazzella Diego Gazzolo Pasquale B Lantieri Wanda Bonacci Giovanni Serra 《The journal of maternal-fetal & neonatal medicine》2006,19(6):343-346
BACKGROUND: Recently we demonstrated an increased 2,3-diphosphoglycerate (2,3-DPG) erythrocyte concentration in rat pups subjected to nucleotide-enriched artificial feeding. DESIGN: The present study was carried out to test the hypothesis that a possible increase in 2,3-DPG concentration can also be obtained in human neonates who are fed nucleotide-enriched formula. Preterm neonates born or referred to the neonatal intensive care unit of the G. Gaslini Hospital, Genoa University, with a gestational age >30 weeks and <37 weeks were enrolled in our randomized trial. Recruitment took place within 48-72 hours from birth. Only newborns of mothers deciding not to breast-feed were eligible to be randomized for the supplemented group (FN) or non-supplemented group (RF). Breast-fed newborns were considered the control group (C). The study window (for supplementation and blood samples) was restricted to the first two weeks following birth (from the 2nd (t1) to the 16th (t2) day of life). At the end of our study, only 21 neonates were eligible for statistical analysis. RESULTS: The stimulating action of dietary nucleotides on 2,3-DPG concentration failed to be demonstrated; increases in 2,3-DPG concentration that were observed in newborns fed with nucleotide supplemented formula (FN) were comparable to those observed in newborns fed with regular formula (RF) and breast-fed newborns. CONCLUSIONS: The EC recommendation for the amount of nucleotides allowed in formula milk does not seem to be high enough to have positive effects on 2,3-DPG synthesis. Whether this possible 'pharmacological' effect can be achieved by a higher intake of ingested nucleotides and/or a change in the proportions of single nucleotides contained in milk formulas remain interesting end points to be elucidated. 相似文献
105.
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 总被引:1,自引:0,他引:1
106.
107.
108.
Arteaga CL Sliwkowski MX Osborne CK Perez EA Puglisi F Gianni L 《Nature reviews. Clinical oncology》2012,9(1):16-32
The advent of HER2-directed therapies has significantly improved the outlook for patients with HER2-positive early stage breast cancer. However, a significant proportion of these patients still relapse and die of breast cancer. Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing. In addition, promising new approaches are being developed including monoclonal antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 or other HER family members, antibodies linked to cytotoxic moieties or modified to improve their immunological function, immunostimulatory peptides, and targeting the PI3K and IGF-1R pathways. Improved understanding of the HER2 signaling pathway, its relationship with other signaling pathways and mechanisms of resistance has also led to the development of rational combination therapies and to a greater insight into treatment response in patients with HER2-positive breast cancer. Based on promising results with new agents in HER2-positive advanced-stage disease, a series of large trials in the adjuvant and neoadjuvant settings are planned or ongoing. This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research. 相似文献
109.
Michael Weller Nicholas Butowski David D Tran Lawrence D Recht Michael Lim Hal Hirte Lynn Ashby Laszlo Mechtler Samuel A Goldlust Fabio Iwamoto Jan Drappatz Donald M ORourke Mark Wong Mark G Hamilton Gaetano Finocchiaro James Perry Wolfgang Wick Jennifer Green John H Sampson 《The lancet oncology》2017,18(12):e709-e710
110.
Alba A. Brandes Enrico Franceschi Alicia Tosoni Stefania Bartolini Antonella Bacci Raffaele Agati Claudio Ghimenton Sergio Turazzi Andrea Talacchi Miran Skrap Gianluca Marucci Lorenzo Volpin Luca Morandi Stefano Pizzolitto Marina Gardiman Alvaro Andreoli Fabio Calbucci Mario Ermani 《Neuro-oncology》2010,12(3):283-288
O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation status is a prognostic factor in newly diagnosed glioblastoma patients. However, it is not yet clear whether, and if so how, MGMT methylation status may change. Moreover, it is unknown whether the prognostic role of this epigenetic feature is retained during the disease course. A retrospective analysis was made using a database of 614 glioblastoma patients treated prospectively from January 2000 to August 2008. We evaluated only patients who met the following inclusion criteria: age ≥18 years; performance status 0-2; histological diagnosis of glioblastoma at both first and second surgery for recurrence; postoperative treatment consisting of: (i) radiotherapy (RT) followed by adjuvant temozolomide (TMZ) until 2005 and (ii) TMZ concurrent with and adjuvant to RT after 2005; a time interval ≥3 months between first and second surgery. MGMT status was evaluated at first and second surgery in all 44 patients (M:F 32:12, median age: 49 years, range: 27–67 years). In 38 patients (86.4%), MGMT promoter status was assessable at both first and second surgery. MGMT methylation status, changed in 14 patients (37%) of second surgery samples and more frequently in methylated than in unmethylated patients (61.5% vs 24%, P = .03). The median survival was significantly influenced only by MGMT methylation status determined at first surgery (P = .04). Significant changes in MGMT methylation status during the course of GBM occur more frequently in MGMT methylated than unmethylated cases. MGMT methylation status determined at first surgery appears to be of prognostic value; however, it is not predictive of outcome following second surgery. 相似文献